
VC-backed Themis announces IPO price range
Austria-based Themis Bioscience, backed by a consortium of VC investors, is set to list on Euronext Amsterdam on 9 November with an indicative offering price of €9.70-11.60 per share.
The offering will consist of 3,608,247 offer shares. The overallotment option of additional ordinary shares is equal to up to 15% of the offer shares subscribed for in the offering, so the offering could total 4,149,484 if the extension clause and overallotment option are fully exercised.
The size of the offering will be approximately €35m based on the low-end of the price range and €55.3m based on the high-end of the price range. Assuming the mid-point in the pricing range is achieved, Themis will achieve a market cap of around €138.95m.
A pre-money valuation in the €85.4m-102.1m range is implied.
Backers US-based Global Health Investment Fund, Austria-based Gründerfonds Beteiligungs, France-based Ventech, and private investor Werner Lanthaler have committed to subscribe for shares in the offering, for an aggregate amount of €8.6m.
The company has also secured an investment from funds managed by Omnes Capital of €1.4m in convertible loan notes that will convert at settlement at the offer price.
Themis anticipates using the net proceeds of the offering to conduct the phase-III clinical trials for chikungunya, as well as driving research and development of its MV platform towards the immuno-oncology field and expanding commercialisation capabilities.
The business has been backed by VC firms since 2011, when Ventech led a €5m series-A funding round for Themis. The investor returned in November 2016 to take part in a €10m series-B along with AWS Gründerfonds, Omnes Capital and Wellington Partners. In January this year, GHIF led a €10m series-C round, with AWS Gründerfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences also taking part.
Vienna-based Themis Bioscience was founded in 2009 and is a specialist developer of vaccines for emerging infectious diseases. The company has developed vaccine products for dengue and chikungunya fevers and is working on zika, respiratory syncytial virus (RSV), norovirus and cytomegalovirus, as well as other applications of immune system activation. The products are based on a new vaccine vector technology, developed by the Institut Pasteur in Paris, with which Themis collaborates.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater